ARA-290
Last reviewed June 3, 2026
Also known as: Cibinetide, ARA290, Cyclic helix B peptide
Quick Answer
ARA-290 is a epo receptor agonist research compound (not FDA-approved for human use) studied for neuropathic pain relief. ARA-290 is a peptide modeled on erythropoietin that activates the body's tissue-repair pathway without the blood-thickening effects of EPO, studied primarily for neuropathic pain and nerve regeneration. Research dose: 4–4 mg daily x 28 days. Half-life: 2 minutes. Available from COA-verified vendors with code PEPTIDEX for up to 20% off.
Where to Source
Ranked by $/mg1Bio Longevity Labs Best $/mg
$80.75
$95.00Save $14.25
15mg vial
$6.33/mg
99%+ purityTested May 2026
Use code for 15% off:
Shop Bio Longevity Labs Compare all 1 vendors →
Rankings independent · Research use only
Selectively activates the innate repair receptor (IRR), a heterodimer of the erythropoietin receptor (EPOR) and CD131 (βc receptor). Unlike full erythropoietin, ARA-290 binds only the IRR and not the
Where to Buy ARA-290
COA-verified vendors · Use code PEPTIDEX for up to 20% off
* Prices for research peptide acquisition. Not therapeutic products.
| Vendor | Purity | List Price | With PEPTIDEX | Code | Shop |
|---|---|---|---|---|---|
Bio Longevity LabsTriple-Tested | 99%+ | $95.0015 mg | $80.75Save 15% | PEPTIDEX | * Research vendor — verify your regional regulations before purchase. Shop |
Bio Longevity LabsTriple-Tested
$95.00 · 15 mg$80.75−15%
Use code PEPTIDEX for 15% off at Bio Longevity Labs.
* Research vendor — verify your regional regulations before purchase.
Shop at Bio Longevity Labs§ Mechanism of Action
Selectively activates the innate repair receptor (IRR), a heterodimer of the erythropoietin receptor (EPOR) and CD131 (βc receptor). Unlike full erythropoietin, ARA-290 binds only the IRR and not the classical erythropoietic homodimer receptor, conferring tissue-protective and anti-inflammatory effects without affecting red blood cell production, hematocrit, or platelet aggregation. Reduces corneal nerve fiber loss and improves small fiber neuropathy symptoms.
§ Primary Benefits
- 1Neuropathic pain relief
- 2small fiber neuropathy
- 3anti-inflammation
- 4tissue protection
§ Clinical Evidence
ARA 290 improves symptoms in patients with sarcoidosis-associated small fiber neuropathy
Culver et al. (Molecular Medicine): Phase 2 RCT — ARA-290 significantly improved neuropathic pain scores, fatigue, and corneal nerve fiber density in sarcoidosis patients with small fiber neuropathy vs placebo.
ModerateARA-290 reduces corneal nerve fiber density loss in painful diabetic neuropathy
Van Velzen et al.: ARA-290 treatment stabilized corneal nerve fiber loss and reduced neuropathic pain scores in a diabetic neuropathy cohort, demonstrating nerve-protective effects.
ModerateThe innate repair receptor mediates the anti-inflammatory and tissue-protective actions of EPO
Brines et al.: Defines the IRR as the mechanistic target for tissue protection, distinguishing it from the erythropoietic receptor and validating selective IRR agonists as safe alternatives to EPO.
Preclinical§ Safety Profile
Has completed Phase 2 human trials. Very short plasma half-life (~2 minutes) but prolonged pharmacodynamic effect. No erythropoietic activity — does not raise hematocrit. Well tolerated in trials. Not FDA-approved. Research only.
See our evidence grading methodology for how we evaluate and grade peptide safety data.
§ Dosing Protocol
* Dosing data from published literature — not a human use recommendation.
RouteSubQ
Dose Range4000–4000 mcg
FrequencyDaily x 28 days
TimingMorning
Cycle Length4–4 weeks
Phase 2 trial dose: 4mg SubQ daily for 28 days. Very short plasma half-life (~2 min) but prolonged downstream signaling.
§ Pharmacokinetics
⏱️ Half-Life: 2min
Plasma concentration over time§ Expected Outcomes
Weeks 2–4
Neuropathic pain scores begin improving; corneal nerve fiber stabilization
Month 2–3
Sustained reduction in fatigue and pain in sarcoidosis neuropathy models
§ Adverse Effects
| Side Effect | Incidence | Severity |
|---|---|---|
Injection site reaction | ~10% of trial participants | mild |
Mild headache | ~8% | mild |
Where to Source ARA-290 for Research
Finding verified, high-purity ARA-290 requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified ARA-290✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
PEPTIDEX coupon for ARA-290Save 20% on ARA-290 at Amino Club & verified vendors →
Reconstitution CalculatorCalculate reconstitution for ARA-290 →
Compare ToolCompare ARA-290 to similar peptides →
Cite This Page
⚠️ Educational only · Not medical advice · For research use only. Information on this page is compiled from peer-reviewed literature and is intended strictly for educational and informational purposes. Peptides discussed may be unapproved research chemicals — consult a licensed healthcare professional before considering any peptide compound. Read our full disclaimer
Affiliate disclosure: PeptiDex may earn commissions from purchases made through vendor links on this page. This does not affect our editorial ranking or vendor recommendations — we exclusively feature vendors that pass independent COA verification. See our methodology · Editorial policy
Free Download
2026 Peptide Stack Cheat Sheet
12stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
§ About the Author Verified
PeptiDex Research
Independent researcher, not a medical professional
PeptiDex Research is the byline used by the independent researcher who builds and maintains PeptiDex. The site is a one-person research project — there is no editorial board, no medical reviewers, and no clinical staff. Content is produced by reading...
View profileLast fact-checked: · PeptiDex Editorial Team